Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.
H. Lee Moffitt Cancer Designated A Comprehensive Cancer Center By NCI.
DeMets Receives Lectureship On Epidemiology From NIH.
Generic Paclitaxel Approval Withstands Court Challenge.
Obit: J. Gale Katterhagen, NCAB’s First Community Physician.
NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.
FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.
M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.
Genetronics Phase II Trials For Head & Neck Completed.
Biomira Ends Agreement On Lymphoma Vaccine.
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored
